1. The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis
   Guangzhi Ma et al, 2018, Clinica Chimica Acta CrossRef
2. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma
   Taichi Matsubara et al, 2019, Annals of Surgical Oncology CrossRef
3. Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data
   Gustavo Dix Junqueira Pinto et al, 2016, Journal of Immunology Research CrossRef
4. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis
   Xiaochun Lin et al, 2021, International Immunopharmacology CrossRef
5. PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients
   Haifeng Xia et al, 2017, Clinica Chimica Acta CrossRef
6. Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
   Ramy R. Saleh et al, 2022, Molecular Diagnosis & Therapy CrossRef
7. Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis
   Ross A. Soo et al, 2018, Oncotarget CrossRef
8. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
   Karina Kulangara et al, 2019, Archives of Pathology & Laboratory Medicine CrossRef
9. Characteristics and Predictive Value of PD-L1 Status in Real-World Non–Small Cell Lung Cancer Patients
   Jeng-Sen Tseng et al, 2018, Journal of Immunotherapy CrossRef
10. L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation
    Shuwen Han et al, 2017, Oncology Letters CrossRef
11. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
    Minghui Zhang et al, 2017, Scientific Reports CrossRef
12. The Expression and Clinical Signification of PD-1 in Lymph Nodes of Patients with Non-small Cell Lung Cancer
    Haitao Ma et al, 2017, Immunological Investigations CrossRef
13. Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers
    Robin Veenstra et al, 2018, Laboratory Investigation CrossRef
14. Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines
    Lingyun Yang et al, 2017, International Journal of Gynecologic Cancer CrossRef